Physician profile
Edward Moore
NPI 1578803649
$1,897.99
in general payments reported to CMS, 2019-2025
27 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $31.02 · 2021: $122 · 2022: $373 · 2023: $424 · 2024: $590 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.77 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $173.11 | 2021-2024 | Farxiga, Airsupra |
| Amgen INC. | $146.74 | 2021-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $116.34 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.93 | 2022-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $98.42 | 2023-2024 | Austedo Xr |
| Lilly USA, LLC | $93.78 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $93.69 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $79.79 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $77.45 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $55.31 | 2020-2025 | Arexvy, Shingrix |
| Pfizer INC. | $46.90 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $46.69 | 2022-2024 | Invega Sustenna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.17 | 2019-2024 | Jardiance |
| Lundbeck LLC | $43.11 | 2023-2024 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $35.79 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $34.72 | 2025 | Invega Sustenna |
| Braeburn INC. | $26.95 | 2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $26.36 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.31 | 2024 | Horizant |
| Ardelyx, INC. | $22.97 | 2024 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $21.29 | 2022 | |
| Bausch Health US, LLC | $19.45 | 2024 | Aplenzin |
| Inspire Medical Systems, INC. | $17.97 | 2024 | Inspire |
| Neurelis, INC. | $16.04 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.